Currently available GLP-1 receptor agonists in the United States include exenatide (Byetta, Bydureon BCise), liraglutide (Victoza, Saxenda), dulaglutide (Trulicity), semaglutide (Ozempic, Wegovy, Rybelsus), and tirzepatide (Mounjaro, Zepbound), though tirzepatide is technically a dual GIP/GLP-1 receptor agonist
Nutritional deficiencies may develop if weight loss is too rapid or dietary intake becomes overly restricted
State and territory attorneys general urge FDA to take action against counterfeit and illegally sold GLP-1 drugs
For example, people with type 2 diabetes may be more likely to experience low blood sugar on semaglutide, especially if they are also taking insulin, which also helps to lower blood sugar levels